197 F. Supp. 3d 557
S.D.N.Y.2016Background
- QRx Pharma (Australian) developed MoxDuo (combination of morphine and oxycodone) and filed NDAs for U.S. approval; Holaday was CEO during the Class Period (Dec 6, 2010–Apr 23, 2014).
- FDA review implicated the federal “Combination Rule” (21 C.F.R. §300.50); FDA review team ultimately treated same-class dual-opioid combos as needing a showing of superiority (safety or efficacy) over equi-analgesic doses of components.
- QRx completed Phase III Study 008 (compared combination to component doses used in the combo) and conducted Study 022 (designed to compare MoxDuo to equi-analgesic doses); QRx submitted an NDA in 2011 and resubmissions in 2013.
- FDA issued a Complete Response Letter (CRL) in June 2012 requesting more evidence (including Study 022 data); QRx resubmitted but FDA issued another CRL in Aug 2013; FDA materials and an Advisory Committee recommended against approval in April 2014.
- Plaintiffs (investors who bought ADRs) alleged §10(b)/Rule 10b-5 and §20(a) claims, saying QRx and Holaday concealed the FDA’s “Superiority Requirement” and setbacks, inflating ADR prices; QRx later was dismissed from the case via bankruptcy recognition, leaving Holaday as sole defendant.
- The district court granted Holaday’s motion to dismiss the Second Amended Complaint in full for failure to plead falsity, materiality, and scienter (and dismissed the §20(a) claim as derivative of the deficient §10(b) claim).
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether challenged pre-CRL statements about Study 008 / NDA were misleading by omission of the FDA’s asserted Superiority Requirement | Plaintiffs: FDA had privately told QRx the Superiority Requirement applied and Study 008 could not satisfy it; failure to disclose was misleading | Holaday: NAL text and context do not establish FDA had adopted that construction pre-CRL; no duty to disclose interim FDA feedback absent its making other statements misleading | Court: Pre-CRL statements not actionable; the NAL does not support plaintiffs’ claim and omissions were immaterial or protected (safe harbor for forward-looking statements) |
| Whether post-CRL statements (June 2012 onward) were misleading by omission of the FDA’s application of the Superiority Requirement | Plaintiffs: After the CRL defendants still omitted that FDA required superiority to equi-analgesic doses, and thus gave false optimism | Holaday: Company disclosed the CRL, the need for more data (Study 022), and appeals; disclosures put market on notice the FDA sought additional proof—no further disclosure necessary | Court: Most post-CRL statements truthful and not misleading given disclosures and context; one close statement (Jan 24, 2013) arguably misleading but not proven with scienter |
| Whether plaintiffs adequately pleaded scienter as to Holaday | Plaintiffs: Holaday received the NAL/CRL, resigned shortly after, and gave evasive investor-call answers—supports inference of intent or recklessness | Holaday: No motive (no suspicious insider sales), continued investment in clinical program inconsistent with belief NDA was doomed; omissions and imprecision are at most negligence | Court: Scienter not adequately pled—no cogent motive/opportunity, alleged facts better explained by honest belief, negligence, or sloppy drafting rather than intent or recklessness |
| Whether §20(a) control-person claim against Holaday survives absent a primary violation | Plaintiffs: Holaday as CEO exercised control and is liable if primary violation is shown | Holaday: Primary §10(b) claim fails, so control-person claim fails too | Court: §20(a) claim dismissed because plaintiffs failed to plead a primary securities violation |
Key Cases Cited
- Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (pleading must state a plausible claim)
- Ashcroft v. Iqbal, 556 U.S. 662 (court need not accept legal conclusions)
- Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (scienter inference standard in securities cases)
- Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (materiality and omission principles in securities fraud)
- Basic Inc. v. Levinson, 485 U.S. 224 (materiality standard for securities disclosures)
- TSC Indus., Inc. v. Northway, Inc., 426 U.S. 438 (total mix materiality formulation)
- Novak v. Kasaks, 216 F.3d 300 (2d Cir.) (recklessness standard and pleading scienter)
- ATSI Communications, Inc. v. Shaar Fund, Ltd., 493 F.3d 87 (2d Cir.) (heightened pleading under Rule 9(b) and PSLRA)
- Kalnit v. Eichler, 264 F.3d 131 (2d Cir.) (motive-opportunity and recklessness guidance)
- Tongue v. Sanofi (Sanofi II), 816 F.3d 199 (2d Cir.) (Omnicare/Omnicare-of-opinions guidance applied)